Tonix Pharmaceuticals (NASDAQ: TNXP), a fully integrated, commercial-stage biotechnology company, will host a conference call and webcast on Monday, Nov. 9, 2026, at 8:30 a.m. ET to report third-quarter 2026 financial results and operational highlights, the company announced.
The scheduled update matters because Tonix is no longer only a clinical-stage story. Its flagship medicine, TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), is described as the first new treatment for fibromyalgia in more than 15 years. That approval gives the company a commercial product in a condition that has long lacked fresh therapeutic options, and the quarterly report will be the clearest public measure of how that launch is progressing alongside the company's broader business.
Investors and interested parties can register to participate in the conference call or view the webcast through the company, and a replay will be available under “IR Events” in the Investors section of the Tonix website. For readers who want the full announcement, the complete press release is available at https://nnw.fm/va44Q.
Tonix focuses on central nervous system and immunology treatments in areas of high unmet medical need. Its CNS commercial infrastructure supports marketed products including the acute migraine treatments Zembrace SymTouch and Tosymra. Beyond the commercial portfolio, the company is maximizing the science behind TONMYA in Phase 2 clinical trials evaluating its potential in major depressive disorder and acute stress disorder, and its CNS pipeline includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease.
Tonix is also advancing immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. The company notes that its product development candidates are investigational new drugs or biologics whose efficacy and safety have not been established and which have not been approved for any indication.
The implications extend beyond a single earnings date. A commercial-stage biotech with a newly approved flagship product and several mid-stage programs faces scrutiny on both revenue traction and pipeline execution, and the Nov. 9 call offers management a platform to address both. The latest news and updates relating to TNXP are available in the company's newsroom at https://nnw.fm/TNXP.
The announcement was distributed through NetworkNewsWire, a specialized communications platform focused on financial news and content distribution for private and public companies and the investment community. It is one of more than 75 brands within the Dynamic Brand Portfolio at IBN, which provides wire solutions through InvestorWire and other services. Terms of use and disclaimers applicable to the content are posted at https://www.NetworkNewsWire.com/Disclaimer.
